Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

L-DOS 47

Next Previous
Drug Profile

L-DOS 47

Alternative Names: L-DOS47

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Helix BioPharma
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Ureases
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Lung cancer; Non-small cell lung cancer
  • Phase I/II Pancreatic cancer

Most Recent Events

  • 10 Apr 2025 Helix BioPharma plans a phase II trial for Non-small cell lung cancer (Combination-therapy) in 2025
  • 11 Mar 2025 Pharmacodynamics data from a preclinical trial in Solid tumours released by Helix BioPharma
  • 24 Oct 2024 Helix BioPharma terminates a phase-I/II clinical trials in Pancreatic cancer (Recurrent, metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) due to budget constraint (NCT04203641)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top